Limited Availability: $799 preorder (reg. $1,299). Save $500. Reserve for $49 →
Home
The Science
Cancer
How It Works
Pricing
About
Contact
EN FR DE 简体 繁體
Reserve Your Test for $49
Warm light representing hope and early detection

Detecting Cancer Early.
One Blood Draw.

Most cancers in Canada have no screening program. miCheckup screens for signals across multiple solid tumor cancers from a single blood draw.

Reserve Your Test for $49

Preorder $799 · Regular $1,299 · Save $500

Home › Cancer
The Gap Cancer in Canada Beyond Cancer Reserve for $49
The Screening Gap

Most cancers have no screening test. That's the problem miCheckup exists to solve.

Most cancers have no public screening program in Canada. They are detected only after symptoms appear — often too late.

Canada's public healthcare system offers population-level screening for exactly three cancers: breast (mammography), cervical (Pap/HPV), and colorectal (FIT/colonoscopy). For every other cancer, there is no routine screening available to asymptomatic Canadians.1

This means cancers like pancreatic, ovarian, liver, kidney, bladder, stomach, lung (for non-smokers), esophageal, and uterine cancers are diagnosed only when symptoms appear. By that point, the cancer has often progressed to a stage where treatment options are limited and survival rates drop dramatically.

miCheckup addresses this gap with a single blood test that screens for microRNA signals across multiple non-breast solid tumor cancers simultaneously — including many that have no public screening program at all. It is not a replacement for existing screening. It is a complement that fills the gap where no screening exists.

Early detection saves lives. When cancer is caught at stage I, the five-year survival rate for many cancers exceeds 90%. When caught at stage IV, that number can drop below 10%. The difference is screening — and for most cancers in Canada, that screening simply doesn't exist.

How It Works
Advanced research laboratory

Cancer in Canada — by the numbers.

240,000+
New cancer cases diagnosed in Canada every year — a number that continues to rise
Only 3
Cancers have public screening programs in Canada — breast, cervical, and colorectal
1 in 2
Canadians will be diagnosed with cancer in their lifetime
Cancer in Canada

The reality of cancer in Canada.

These are some of the most common cancers diagnosed in Canada every year — and most have no public screening program.

The following statistics are based on data from the Canadian Cancer Society.1

Lung Cancer31,000 cases/year in Canada. The #1 cancer killer. No screening for non-smokers.
Colorectal Cancer26,900 cases/year. Public screening exists (FIT), but uptake is low and the test misses many cancers.
Prostate Cancer34,000 cases/year. PSA testing is controversial and not universally recommended.
Pancreatic Cancer6,900 cases/year. 10% five-year survival. No screening program. Often diagnosed at stage IV.
Ovarian Cancer3,100 cases/year. No screening program. Known as the "silent cancer" — 75% diagnosed late.
Liver Cancer3,900 cases/year. No population screening. Rising incidence in Canada.
Kidney Cancer8,100 cases/year. No screening. Most found incidentally during imaging for other conditions.
Bladder Cancer13,500 cases/year. No screening. Often misdiagnosed as urinary tract infections.
Stomach Cancer4,300 cases/year. No screening in Canada. Symptoms overlap with common GI conditions.
Uterine Cancer8,400 cases/year. Most common gynecological cancer. No screening program.
Head & Neck Cancer6,100 cases/year. Rising sharply due to HPV. No population screening.
Esophageal Cancer2,400 cases/year. 15% five-year survival. No screening. Usually diagnosed late.

Source: Canadian Cancer Society, Canadian Cancer Statistics 2024. Screening program availability based on provincial guidelines as of 2024.4

View the Science
Healthcare professional reviewing results
Beyond Cancer

microRNA sees more than cancer.

miCheckup is built on a microRNA multi-disease screening (MMDS) platform — a technology designed to go far beyond cancer detection.

The same microRNA science that powers miCheckup's multi-cancer early detection is not limited to cancer. microRNA patterns change with all disease — including cardiovascular disease, neurodegenerative conditions, and more.

This is the vision behind the microRNA multi-disease screening (MMDS) platform. Today, miCheckup applies the MMDS platform to cancer. Tomorrow, the same blood sample and the same analytical framework may extend into:

  • Cardiovascular health — microRNA patterns associated with coronary artery disease, heart failure, and other cardiovascular conditions are well-documented in peer-reviewed research
  • Neurological health — miRoncol is actively researching microRNA signatures associated with neurodegenerative conditions, including Alzheimer's disease

Your microRNA data from today captures molecular information that extends far beyond cancer. As the MMDS platform evolves, your baseline data may become the foundation for future health insights across multiple disease domains.

Learn About the MMDS Platform
Research laboratory with molecular analysis equipment

miCheckup — validated science, real results.

99%+
Specificity — fewer than 1 in 100 people without cancer receive a false signal
>90%
Sensitivity for the majority of cancer types in peer-reviewed validation
Thousands
Peer-reviewed blood samples used to validate the miCheckup microRNA model

Most cancers have no screening in Canada. miCheckup fills the gap.

One blood draw. Physician-reviewed results. Whole-body MRI included if a cancer signal is identified.

Reserve Your Test for $49

Preorder $799 · Regular $1,299 · Save $500

Important Safety Information

+

miCheckup is intended for adults at or above the age of majority in their province (18 or older in most provinces; 19 or older in British Columbia, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, and Yukon). miCheckup is a multi-cancer early detection (MCED) test — an early warning test intended to identify a suspected cancer signal associated with multiple solid tumor cancers from a single blood draw. miCheckup does not detect all cancers and should be used in addition to routine cancer screening tests recommended by your healthcare provider.

Use of miCheckup is not recommended in individuals who are pregnant or planning pregnancy, under the age of majority in their province, currently undergoing active cancer treatment, or currently experiencing symptoms that may indicate cancer. If you are experiencing symptoms, please consult your physician directly.

Results should be interpreted by a healthcare provider in the context of your medical history, clinical signs, and symptoms. All miCheckup results are reviewed with you by a physician. A result of "no suspected cancer signal identified" does not rule out cancer. A result of "suspected cancer signal identified" is not a diagnosis — it requires confirmatory diagnostic evaluation by medically established procedures, which is why a whole-body MRI and physician follow-up are included in your miCheckup test.

If a suspected cancer signal is identified but cancer is not confirmed with further testing, it could mean that cancer is not present, or that testing was insufficient to detect cancer — including due to the cancer being located in an area or of a type not well represented in the miCheckup signal. False positive results (a suspected cancer signal identified when cancer is not present) and false negative results (no suspected cancer signal identified when cancer is present) do occur.

miCheckup is a complement to, not a replacement for, standard cancer screening programs. Continue all recommended screening — including mammography, Pap/HPV testing, and colorectal screening (FIT or colonoscopy) — as directed by your healthcare provider. Cancer diagnosis in Canada always requires a tissue biopsy confirmed by a pathologist. If a suspected cancer signal is identified, imaging and clinical workup by your healthcare team will determine the actual status. Many findings turn out to be benign after further investigation.

Laboratory/Test Information

+

miCheckup is a multi-cancer early detection (MCED) Laboratory-Developed Test (LDT), performed at an accredited Canadian medical laboratory certified by the Institute for Quality Management in Healthcare (IQMH). In Canada, LDTs are regulated as a clinical laboratory service under provincial and territorial laboratory oversight. Your blood sample is collected, processed, and analyzed entirely within Canada.

The miCheckup microRNA analysis is based on peer-reviewed research published in Scientific Reports (Nature Portfolio, 2024) and Cancers (MDPI, 2022), validated on thousands of peer-reviewed blood samples, with ongoing validation through the Ontario Health Study using 4,000+ Canadian blood samples.

Published validation shows greater than 99% specificity and greater than 90% sensitivity for the majority of cancer types in the current miCheckup panel of multiple solid tumor cancers. Performance may vary by cancer type and individual factors. For a detailed breakdown of sensitivity and specificity by cancer type, and the complete list of cancers currently in the miCheckup panel, visit The Science.

All personal health data is stored in Canada and handled in accordance with the Personal Information Protection and Electronic Documents Act (PIPEDA) and applicable provincial health privacy legislation, including the Personal Health Information Protection Act (PHIPA) in Ontario.

miCheckup is currently available in Ontario, expanding across Canada. For the full safety, regulatory, and performance disclosure, see Important Information.

References

+
  1. Canadian Cancer Society. Canadian Cancer Statistics 2024. cancer.ca/statistics
  2. Zhang J, Rui H, Hu H. "Noninvasive multi-cancer detection using blood-based cell-free microRNAs." Scientific Reports 14, 22136 (2024). doi.org
  3. Zhang A, Hu H. "A Novel Blood-Based microRNA Diagnostic Model with High Accuracy for Multi-Cancer Early Detection." Cancers 14(6), 1450 (2022). doi.org
  4. Thériault, G. et al. "Cancer screening in Canada: What's in, what's out, what's coming." Canadian Family Physician 67(1), 27–29 (2021). pmc.ncbi.nlm.nih.gov